Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug EPI-326 enters first human tests for tough cancers

NCT ID NCT07462377

Recruiting now Disease control Sponsor: EpiBiologics Source: ClinicalTrials.gov ↗

First seen Mar 19, 2026 · Last updated Jun 18, 2026 · Updated 18 times

Summary

This early-phase study tests a new drug called EPI-326 in people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to check safety and find the best dose. About 110 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Astera Cancer Care

    RECRUITING

    East Brunswick, New Jersey, 08816, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MD Anderson Cancer Center

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START Los Angeles

    RECRUITING

    Los Angeles, California, 90025, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • START New York Long Island

    RECRUITING

    Lake Success, New York, 11042, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sarah Cannon and HCA Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • South Texas Accelerated Research Therapeutics (START)

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma non-small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR EGFR EPIDERMAL GROWTH FACTOR EPIDERMAL GROWTH FACTOR RECEPTOR EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION HEAD AND NECK HEAD AND NECK CANCER HEAD AND NECK CANCERS HEAD AND NECK CANCERS HEAD AND NECK SQUAMOUS CELL CANCER HEAD AND NECK SQUAMOUS CELL CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC HNSCC NON SMALL CELL NON SMALL CELL NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG NON-SMALL CELL LUNG NON-SMALL CELL LUNG CANCER NSCLC (NON-SMALL CELL LUNG CANCER)